Finally we will have a treatment option for this age group
Chronic spontaneous urticaria affects 0.5-1% of children but lacked approved treatments for those under 12 until Brazil's December 2025 regulatory approval. The new therapy targets type 2 inflammation, a specific immune mechanism also involved in asthma and atopic dermatitis, enabling more personalized treatment approaches.
- Brazil approved the first immunobiological therapy for chronic spontaneous urticaria in children aged 2-11 in December 2025
- The condition affects 0.5-1% of the pediatric population but had no approved treatments for children under 12 until this approval
- The therapy targets type 2 inflammation, a specific immune mechanism also involved in asthma and atopic dermatitis
Brazil became the first country to approve an immunobiological therapy for chronic spontaneous urticaria in children aged 2-11, addressing a long-standing treatment gap. The approval aligns with updated international guidelines recognizing type 2 inflammation mechanisms in the disease.
A child wakes in the night scratching at welts that appeared without warning. By morning they fade, but the exhaustion lingers. The itch returns by afternoon—red patches that burn and sting, sometimes swelling in the lips or eyelids, disrupting sleep, derailing schoolwork, isolating the child from friends. For families living with chronic spontaneous urticaria, or UCE, this is not occasional discomfort but a relentless condition that reshapes daily life.
UCE is defined by symptoms that persist daily or nearly daily for more than six weeks. The disease is poorly understood by the general public, yet it carries profound weight for those it affects. The itching is intense. The welts leave no marks but arrive unpredictably and vanish hours later, only to return. Swelling can strike the lips, eyelids, or other body parts. Beyond the visible skin manifestations lies a deeper disruption: sleep fractures, school performance declines, social withdrawal, emotional strain on both child and family.
For decades, children under twelve had no approved treatment specifically designed for them. That changed in December 2025, when Brazil became the first nation in the world to approve an immunobiological therapy targeting the disease in children aged two to eleven. The approval addresses a gap that had persisted despite the condition affecting between 0.5 and 1 percent of the pediatric population. Months later, the updated International Guideline for the Definition, Classification, Diagnosis, and Management of Urticaria formally incorporated this therapy among its recommended advanced options for specific patient profiles.
The breakthrough rests on a shift in scientific understanding. Researchers have identified type 2 inflammation as a central mechanism in UCE—a specific form of immune response the body normally deploys against parasites. When functioning properly, this response protects the organism and promotes tissue healing. But when it becomes excessive or dysregulated, it triggers allergic and chronic inflammatory diseases, including UCE. The same inflammatory pattern appears in asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Dr. Régis Campos, coordinator of Allergy and Immunology at the University Hospital Complex Professor Edgard Santos and acting president of the Brazil Urticaria Network, explains that the word "spontaneous" does not mean the disease lacks a cause—rather, it has no specific external trigger like a food allergy or medication reaction. Understanding type 2 inflammation opened the door to treatments that address the actual mechanism driving the disease.
This precision matters profoundly in pediatrics. The updated international guideline now recognizes that urticaria is heterogeneous—different patients have different underlying drivers. Treatment can now be tailored to individual characteristics, including the presence of related type 2 inflammatory conditions or specific immunoglobulin E levels. Dr. Larissa Brandão, a pediatric allergist and immunologist at the Federal University of São Paulo, calls the new approval a historic gap-filler. "We are quite optimistic about this therapy for children above two years because it addresses a need that has existed for a very long time," she says. "Finally we will have a treatment option for this age group and we hope to meet demands that, until now, were not addressed in this population."
The human stakes extend beyond physical discomfort. Uncontrolled symptoms compromise concentration, school achievement, and emotional development. For Gustavo San Martin, founder of the Association Chronic Day-to-Day, the shift toward personalized treatment represents something deeper than new medication. It means recognizing what was previously unnamed, and offering hope to people who had begun to lose faith in work, social life, and relationships. The science has caught up to the suffering. Now the question is how quickly the therapy reaches the children who need it.
Citas Notables
When we can individualize a disease as heterogeneous as chronic spontaneous urticaria, we begin to recognize what we didn't even know how to name not long ago, and we can give hope to people who have lost faith in work, social life, and relationships.— Gustavo San Martin, founder of the Association Chronic Day-to-Day
Finally we will have a treatment option for this age group and we hope to meet demands that, until now, were not addressed in this population.— Dr. Larissa Brandão, pediatric allergist and immunologist at the Federal University of São Paulo
La Conversación del Hearth Otra perspectiva de la historia
Why did Brazil move first on this approval? Was there something particular about the regulatory environment there?
The source doesn't explain the regulatory pathway specifically, but the timing suggests Brazil's health authorities recognized both the scientific evidence and the unmet need. A condition affecting half to one percent of children with zero approved treatments is a clear gap. Once the immunological mechanism became clear, the case for action became harder to ignore.
When you say type 2 inflammation, that sounds like it could apply to lots of diseases. Why is this therapy specific to urticaria?
Exactly—type 2 inflammation shows up in asthma, eczema, chronic sinus disease. But the new therapy targets it in a way that works for urticaria specifically. The international guideline update recognizes that different patients have different profiles. Some have low IgE levels, some have related conditions. The therapy works for certain patterns, not all urticaria cases.
A child scratching at night, missing school—how much of this is actually preventable now?
That's the hope, but the source doesn't promise a cure. It says the therapy is approved for children two to eleven and represents a treatment option where none existed. Whether it stops the symptoms entirely or just reduces them enough to let a child sleep and concentrate—that will depend on the individual and how the therapy performs in real use.
The disease has no external trigger, so a parent can't just remove an allergen. That must feel helpless.
Yes. With a food allergy, you avoid the food. With UCE, the immune system is misfiring on its own. The child and family live with unpredictability. That's why understanding the mechanism—type 2 inflammation—matters so much. It gives doctors something to actually target instead of just managing symptoms.
What happens to children who still don't respond to this therapy?
The source doesn't address that. It celebrates the approval and the gap it fills, but doesn't discuss what happens for non-responders or whether there are other options in the pipeline. That's the next question.